Melanotan II
A melanocortin analogue commonly discussed for tanning and cosmetic interest but not approved as an FDA drug.
Also appears in: Hormone
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Skin & Cosmetic. Also surfaces under Hormone for browsing and discovery.
No major aliases are tracked for this profile yet.
No FDA label signal · 1 trials · 197 PubMed results
Melanotan II has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Melanotan II has 1 name-matched clinical trial (highest phase: Phase 2) and 197 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What melanotan II is
Melanotan II is a melanocortin analogue that appears frequently in online tanning and cosmetic conversations. It is one of the better-known examples of a peptide with strong consumer curiosity but no FDA-approved status.
Why it matters
It helps define the difference between cosmetic-demand peptides and clinically grounded peptide therapies.
Regulatory context
Melanotan II is not FDA approved in the United States. It belongs in the research-market bucket.
Practical reading note
Because tanning-related demand can blur aesthetic goals and safety assumptions, this is a category where formal approval status matters a lot.